AOTMiT: Transparency Council, among others, on prenatal diagnosis and off-label indications

The agenda includes:

1. Preparation of a position paper on the qualification of the health care service "Free fetal DNA (cffDNA) testing for non-invasive prenatal diagnosis" as a guaranteed benefit.
2. Preparation of a position paper on the qualification of the healthcare benefit "Placental Growth Factor (PlGF) determination for non-invasive prenatal diagnosis" as a guaranteed benefit.
3. Preparation of a position on the removal of the health care benefit "Determination of alpha-fetoprotein as part of non-invasive prenatal diagnosis".
4. Preparation of a position on the removal of the health care benefit "Determination of estriol as part of non-invasive prenatal diagnosis".
5. Preparation of a position paper on the reimbursement of Jemperla (dostarlimabum) under the drug program "Treatment of patients with endometrial cancer (ICD-10: C54)".
6. Prepare a position paper on the import of Citrulline 200, Citrulline 1000, L-Citrulline for the indications: ornithine transcarbamylase deficiency, carbamylphosphate synthase 1 deficiency, lysinuric protein intolerance.
7. Preparation of an opinion on the project "Program for prevention of type 2 diabetes and cardiovascular diseases for residents of the municipality of Połczyn-Zdrój for 2025-2029 (TOP: 20.10.2024)".
8. Preparation of an opinion on the continuation of reimbursement in off-label indications for the active substance: Propafenonum for the indications: supraventricular arrhythmias other than those specified in the SmPC; supraventricular arrhythmias - prevention of recurrence; cardiac arrhythmias in WPW syndrome other than those specified in the SmPC - in children under 18 years of age; ventricular arrhythmias other than those specified in the SmPC - in children under 18 years of age.
9. Preparation of an opinion on the continuation of reimbursement in off-label indications for the active substance: Mycophenolas mofetil for the indications: steroid-dependent nephrotic syndrome; steroid-resistant nephrotic syndrome; cyclosporine-dependent nephrotic syndrome; lupus nephropathy; vasculitis; IgA nephropathy; systemic lupus erythematosus; systemic scleroderma; post-transplant limb; cornea; tissue or cell transplant condition; inflammatory neuropathy; inflammatory myopathy.
10. Preparation of an opinion on the continuation of reimbursement in off-label indications for the active substance: Metoprololum for the indication: extrasystoles of ventricular origin in children under 18 years of age.

Source: AOTMiT